



Cure CMD Research Grant Policy

Protecting the rights and welfare of human research participants is a top priority of Cure CMD. Federal regulation and Cure CMD policy require that all institutions maintain appropriate policies and procedures for the protection of human subjects. In addition, Cure CMD encourages a research environment in which ethical and productive investigation is valued. If applicable, a copy of the informed consent form for any human subjects for the project as well as proof of current project approval by an Institutional Review Board (or a similar oversight group) must be provided to Cure CMD before funding for a project will be released by Cure CMD.

Similarly, it is a Cure CMD policy that all projects must conform to regulations for the safe and humane treatment of animals. Specifically, Cure CMD stipulates that animals can be used in Cure CMD funded research only when no other means of obtaining scientifically sound, valid, and useful results are available. Furthermore, only the minimum number of appropriate animals required to obtain and validate results should be used; and in cases requiring the death of an animal, only the most appropriate and humane form of animal sacrifice consistent with the purpose of the research shall be employed.

It is Cure CMD's expectation that any results and accomplishments from research it has funded will be made public (preferably through a high quality, peer-reviewed journal article) in order to maximize progress toward understanding treatments and ultimately the discovery of a cure for CMD. Cure CMD also expects that products resulting from research funded by the organization will be made available to other researchers on a reasonable basis. Cure CMD considers an option one year period of exclusivity for the creator laboratory to be reasonable. Furthermore, it is expected that such products will be made available to non-commercial laboratories at cost and to commercial enterprises for a reasonable licensing fee.

Cure CMD will not challenge any decision concerning patent applications that might be made by a grantee for inventions resulting from work performed under a Cure CMD research grant. All inventions or discoveries made in whole or in part with funding from Cure CMD must be reported to Cure CMD at the earliest practical time. The grantee also must notify Cure CMD immediately of any decision to apply for a patent or other legal protection. This information will be kept confidential.

Cure CMD will forward funds for the project to the institution every 6 months in accordance with the project's approved budget, following Cure CMD's receipt of a signed statement from the principal investigator and an authorized institutional officer confirming adherence to Cure CMD policies and stating that the project is proceeding in accordance with the original plan, timetable and budget (or explaining variations from the original expectations). This review can also act as an opportunity in light of unexpected outcomes to redirect the proposed project and scope with approval from both the SMAB and Cure CMD Board of directors. Cure CMD will send the required statement to the principal investigator 30 days prior to the time when the next payment of funds is anticipated, and it must be signed and returned before funds can be released.

In any published report of research funded in part or in whole by Cure CMD research grant, Cure CMD must be cited as a source of funds, and Cure CMD must be sent a copy of the published material or paper.

Within 60 days of the end of the grant period, it is required that a typed written report by the PI on the research that resulted from the Cure CMD grant be sent to Cure CMD Vice Chair.

A final detailed accounting of funds spent is required to be sent to Cure CMD within 60 days of the end of the grant period. If the grant period is longer than one year, then annual financial reports must be filed with Cure CMD on the grant commencement date anniversary. At the end of the grant period, any unused funds must be returned to Cure CMD, unless a letter explaining the situation and requesting an extension of the grant period (without additional funds) is submitted at least 90 days ahead of the end of the grant period and approved by Cure CMD.

Any change in a budget category equal to or greater than 10% of the total research grant amount must be requested ahead of time by the PI to Cure CMD in writing and must be approved by the Cure CMD Board of Directors before being executed.

Cure CMD must be notified immediately if there is any change of either the PI or the institution with which he/she is associated. Furthermore, if the PI is to be absent from the grantee Institution for a time of more than 30 days, Cure CMD must be notified. Cure CMD reserves the right to request a written status report on the progress of research project as well as an accounting of the funds spent as of the request date and to determine the final dispensation of any research grant funds remaining in any such situation.

Cure CMD reserves the right to suspend or cancel a grant at any time at its sole discretion for failure to abide by Cure CMD policies governing research grants. Upon receiving notice of project suspension or cancellation, Cure CMD's financial support of any further work on the project will cease. At that point, the PI must prepare and submit a project status report to Cure CMD, while the grantee's institution must submit a complete accounting of funds expended to date. All unused funds must be returned to Cure CMD immediately upon its request. A grantee may terminate a grant by sending notice in writing to Cure CMD, providing Cure CMD with both a written accounting of funds expended to date and a project status report, and returning all unused funds to Cure CMD.

To properly evaluate the applications, each research grant proposal will be reviewed by members of the Cure CMD SMAB who have not also submitted applications in that grant cycle. Outside reviewers will be utilized to supplement SMAB peer review. The applicant should furnish Cure CMD with a list of 3 individuals who would be appropriate outside reviewers. These individual must be qualified to review your application, have not worked with you during the last 3 years, and have no conflict of interest. In addition, the applicant should make known to Cure CMD at the time of application submission if there are any Cure CMD SMAB members or other outside experts whose review of the application would constitute a conflict of interest.

Some information about research grants awarded by Cure CMD will be made available to its constituents and to the general public. This information

will include the title of the project, the PI, the grantee institution, the amount of the grant award and the abstract provided as part of the grant application. No privileged or confidential information or trade secrets previously identified as such to Cure CMD will be divulged.

The nature of this arrangement is a funding agreement, no employment or agency relationship is hereby created.

The PI and the grantee institution indemnify and hold harmless Cure CMD, its board, officers, agents, advisors, and constituents from any claim, judgment, awarded damage, settlement, liability negligence, or malpractice arising from research or investigation relation to this Cure CMD research grant.